Novigenix, an innovator in precision medicine and liquid biopsy technologies, will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA) analysis, providing a comprehensive view of the patient peripheral tumor and immune signals. It builds on the data that earned Novigenix the prestigious MATWIN award ‘Best 2024 Technology Innovation’ in the field of oncology.
At the core of Novigenix’s presentation is the new multimodal capability of Novigenix’s LITOSeek platform, which integrates host immune response with tumor-derived signals from non-invasive liquid biopsy. By combining mRNA immune profiling with cfDNA, Novigenix has developed predictive capabilities that improve the accuracy of forecasting patient outcomes. This approach provides insights into patient heterogeneity and therapy response, uncovering mechanisms of action and resistance, and driving the development of novel treatments.
